PHARMACIST: Med Guide PROVIDED SEPARATELY AND IS TO BE INCLUDED
WITH PRESCRIPTION FOR EACH PATIENT.
Also available at www.ovationpharma.com.
DESOXYN (methamphetamine hydrochloride tablets, USP), chemically known as (S)-N, (alpha)-dimethylbenzeneethanamine hydrochloride, is a member of the amphetamine group of sympathomimetic amines.
Attention Deficit Disorder with Hyperactivity
DESOXYN tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.
as a short-term (i.e., a few weeks) adjunct in a regimen of weight reduction based on caloric restriction, for patients in whom obesity is refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of DESOXYN tablets (see CLINICAL PHARMACOLOGY) should be weighed against possible risks inherent in use of the drug, such as those described below.
Media Articles Related to Desoxyn (Methamphetamine)
Quitting Meth Addiction Less Successful In Teen Girls Than Boys
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2013.05.03]
A UCLA-led study of adolescents receiving treatment for methamphetamine dependence has found that girls are more likely to continue using the drug during treatment than boys, suggesting that new approaches are needed for treating meth abuse among teen girls...
Published Studies Related to Desoxyn (Methamphetamine)
A retrospective analysis of two randomized trials of bupropion for
methamphetamine dependence: suggested guidelines for treatment
BACKGROUND: Two clinical trials have shown efficacy for bupropion in treating
methamphetamine (MA) dependence among those with moderate baseline MA use. However, treatment response is highly variable and it is unclear what duration of
treatment is necessary to determine if maintaining the treatment course is
indicated or if discontinuation or augmentation is appropriate.
Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. [2011.11.01]
CONCLUSIONS: Some MA-abusing individuals treated with SSRIs have sustained craving with an increased propensity to relapse during treatment despite psychosocial treatment interventions. Published by Elsevier Ireland Ltd.
Mirtazapine to reduce methamphetamine use: a randomized controlled trial. [2011.11]
CONTEXT: No approved pharmacologic treatments for methamphetamine dependence exist. Methamphetamine use is associated with high morbidity and is a major cofactor in the human immunodeficiency virus epidemic among men who have sex with men (MSM). OBJECTIVE: To determine whether mirtazapine would reduce methamphetamine use among MSM who are actively using methamphetamine... CONCLUSION: The addition of mirtazapine to substance use counseling decreased methamphetamine use among active users and was associated with decreases in sexual risk despite low to moderate medication adherence. Trial Registration clinicalTrials.gov Identifier NCT00497081.
Acute modafinil effects on attention and inhibitory control in methamphetamine-dependent humans. [2011.11]
ABSTRACT. Objective: Individuals who are methamphetamine dependent exhibit higher rates of cognitive dysfunction than healthy people who do not use methamphetamine, and this dysfunction may have a negative effect on the success of behavioral treatments for the disorder...
The influence of depression on treatment for methamphetamine use. [2011.08.01]
OBJECTIVE: To determine whether the presence of comorbid depression influences response to psychological treatment for methamphetamine use... CONCLUSIONS: Over the short term, comorbid depression did not negatively affect response to treatment, with some evidence of a dose-response treatment effect for reduction in depression. This was not maintained at 6 months, indicating that methamphetamine-focused treatment may not enable people with comorbid depression to make sustained improvement at the level of their counterparts without depression. TRIAL REGISTRATION NUMBER: ACTRN12611000355976.
Clinical Trials Related to Desoxyn (Methamphetamine)
Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study [Recruiting]
Methamphetamine use has escalated in recent years. Methamphetamine use has also spread
throughout the country. Although much information has been gathered on the treatment of
cocaine abuse, very little information has been obtained on the treatment of methamphetamine
abuse. One of the first steps in developing appropriate treatment is to examine the effects
of stopping a particular substance's use on individuals abusing that substance. To date this
has not been well studied for people abusing methamphetamine. The purpose of this study is to
better understand and develop accurate ways of measuring symptoms associated with stopping
the use of methamphetamine in people that are abusing methamphetamine. If the withdrawal
symptoms are able to be effectively measured, this will help to develop treatments targeted
at alleviating these symptoms. These symptoms are often associated with relapse to use of
Behavioral Activation and HIV Risk Reduction for Men Who Have Sex With Men With Crystal Meth Abuse [Recruiting]
The purpose of this study is to research a new behavioral treatment to reduce sexual
risk-taking in men who have sex with men (MSM) who abuse crystal methamphetamine (crystal
meth), and are at risk for HIV acquisition. This study proposes using a treatment based on
our original pilot study that incorporates risk reduction and behavioral activation therapy.
In order to help learn what types of treatment programs best help individuals who abuse
crystal meth and engage in sexual risk-taking, we will compare our treatment to a control
group. The treatment group will receive therapy incorporating behavioral risk reduction
counseling with behavioral activation therapy to treat depression, helping individuals
reengage in their life. The control group will receive the risk reduction counseling
without the behavioral activation therapy. The current study hopes to explore the efficacy
of this previous developed treatment in a two-arm pilot randomized controlled trial.
Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin [Recruiting]
This protocol will test the safety, effectiveness and the metabolism and action of prazosin
as a potential therapy for methamphetamine abuse. This will be accomplished by performing a
series of human laboratory studies. In each of these studies, the safety and effectiveness
of the test medication (prazosin) in the treatment of methamphetamine effects will be
determined. The study hypothesis is that prazosin will block the methamphetamine receptor
function, reducing the reinforcing effects of central nervous system effects in humans.
Studying Amphetamine Withdrawal in Humans [Recruiting]
Methamphetamine use is very common in the US and is associated with serious medical and
psychiatric problems. There has also been a significant increase in the number of patients
entering treatment for methamphetamine dependence, however, no pharmacologic treatment has
been identified as effective in treating methamphetamine addiction. Given that withdrawal
from methamphetamine is thought to contribute to relapse to methamphetamine use during early
treatment, it is important to examine potential pharmacologic agents for alleviating
withdrawal. Thus, this study is designed to study methamphetamine withdrawal in humans. To
this end, 30 methamphetamine dependent participants (ages 18-65 years) will be entered into
a 4-week residential study. Urine samples will be obtained at baseline to ensure recent
methamphetamine use. Intake assessments will include cognitive testing, standardized
assessment of depression and anxiety, profile of mood states, methamphetamine selective
severity assessment, methamphetamine withdrawal assessment, sleep quality and quantity, a
pre-attentional measure and attentional measure. Upon admission to the residential
facility, all study participants will be started on (20-30mg) long acting
amphetamine/d-amphetamine and stabilized over the first 5 days. After stabilization
participants will be randomized based on sex, amphetamine withdrawal questionnaire score,
and methamphetamine selective severity assessment score to either continued treatment with
amphetamine/d-amphetamine or placebo for 2 weeks. All subjects will then be placed on
placebo for the last 7 days. The investigators hypothesis is that stopping amphetamine
administration in methamphetamine dependent individuals will negatively impact mood, sleep
and cognitive function in a time-limited fashion that may differ depending upon the measure
and that attentional, but not pre-attentional, measures will be adversely affected in those
receiving placebo compared to those maintained on amphetamine.
Study of Medical Treatment for Methamphetamine Addiction [Recruiting]
Currently there are no medications approved for the treatment of methamphetamine addiction.
Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA)
for the treatment of depression and for cigarette smoking cessation but is not approved by
the FDA for the treatment of methamphetamine addiction. Preliminary research studies suggest
that bupropion may help people receiving treatment for methamphetamine addiction to reduce
or to stop their methamphetamine use. But results of these studies also suggest that
bupropion may help certain groups of patients more than others, such as men versus women and
light versus heavy methamphetamine users, although the reasons for this difference are not
known. One possibility is that a person's genetic make up may influence whether or not they
respond to treatment with bupropion for methamphetamine addiction.
The purpose of the study is to determine if bupropion is can help people reduce or stop
their methamphetamine use and to investigate whether genetic variations influence whether
people respond to treatment with bupropion for methamphetamine addiction, which may help
doctors and patients better decide if treatment with bupropion will be beneficial or not. To
identify possible genetic variations that influence response to bupropion, we will perform
genetic tests on blood or saliva specimens from participants receiving treatment with either
bupropion or placebo (which is a pill that contains no medication) in conjunction with
standard cognitive behavioral therapy drug counseling. We will compare methamphetamine use,
as assessed with urine drug screens, among participants receiving bupropion versus those
receiving placebo to determine if bupropion helps people to reduce or stop their
methamphetamine use. We will then compare the results of the genetic tests among
participants who respond and who do not respond to bupropion. In addition, since the amount
of methamphetamine a person uses was associated with response to bupropion in preliminary
studies, we will also compare the results of genetic testing among persons with heavy versus
light methamphetamine use before entering treatment.
Results of this study have the potential to provide insights into the biology of
methamphetamine addiction and help increase the understanding of how bupropion works. This
information could be useful to develop effective medications for methamphetamine addiction
and to improve the ability of clinicians to provide treatment to patients with
Reports of Suspected Desoxyn (Methamphetamine) Side Effects
Drug Interaction (15),
Toxicity TO Various Agents (15),
Cardiac Arrest (12),
Respiratory Arrest (11),
Intentional Drug Misuse (9),
Completed Suicide (8),
Drug Abuse (7),
Pulmonary Oedema (6),
Sudden Death (5),
Hypotension (4), more >>
Page last updated: 2013-05-03